News
U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback